Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 10 systematic review(s)/meta-analysis(es). ^[1-10]
• Inclisiran significantly reduced LDL (Low-Density Lipoprotein)-C (MACE) levels by -45.48% (95% CI (95% CI: -51.75, -41.13, p<0.01): -50.36%, -40.61%) compared to placebo, with additional reductions in total cholesterol, non-HDL (MD = -39.45%, 95%CI: -43.6%, -35.31%) cholesterol, and apolipoprotein B levels. It also increased HDL-C levels significantly.
• In patients with heterozygous familial hypercholesterolemia (HeFH), inclisiran reduced LDL-C by -48.62%, while in homozygous familial hypercholesterolemia (HoFH), the reduction was -9.12%, showing greater effectiveness in HeFH patients (P < 0.05).
• Comparatively, inclisiran was slightly less effective than evolocumab, which reduced LDL-C by -61.09%, but it showed similar effectiveness to alirocumab (-46.35%).
• Inclisiran demonstrated effectiveness in reducing major adverse cardiac events (MACE), with a significant reduction compared to placebo (RR (0.98,1.12) = 0.79, p = 0.05), making it beneficial for patients with cardiovascular disease.
• Inclisiran was associated with a non-significant elevated risk of total adverse events (RR = 1.05, p = 0.16) and non-serious adverse events (RR = 1.09, p = 0.15) compared to placebo, while the risk of serious adverse events was lower (RR = 0.94, p = 0.67).
• There was a significantly increased risk of injection-site reactions with inclisiran, including any reaction (OR (95% CI: 0.64, 0.81, p<0.01) = 5.86), mild reactions (OR = 5.19), and moderate reactions (OR = 13.37), while there was also an elevated risk of bronchitis (OR = 1.58).
• Liver and kidney function tests, creatine kinase values, and platelet counts showed no significant differences between inclisiran and placebo.
• Inclisiran significantly reduced LDL-C and other lipid parameters in patients with heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH), with a greater reduction in HeFH patients for LDL-C (-48.62% in HeFH vs. -9.12% in HoFH, P < 0.05). It also significantly reduced LDL-C in patients with atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk equivalents, showing consistent effectiveness across these populations.